^
Association details:
| Biomarker: | FGFR2 translocation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | gunagratinib (ICP-192) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Add to Collection
Published date:
05/19/2021
Excerpt:
...patients with cholangiocarcinoma harboring FGFR2 gene fusion/translocation received the treatment of gunagratinib daily at 12 mg continuously….the overall response rate (ORR) was 33.3%, including 1 patient (8.3%) of cholangiocarcinoma with complete response (CR) and 3 patients (25%) with partial response (PR). The disease control rate (DCR) was 91.7% (11 of 12 patients)...Anti-tumor activity was demonstrated in patients with FGF/FGFR gene aberrations in multiple tumor types, including cholangiocarcinoma...
DOI:
10.1200/JCO.2021.39.15_suppl.4092
Trial ID:
